Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.

@article{Flaker2006RisksAB,
  title={Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.},
  author={Greg C. Flaker and Michael Gruber and Stuart J. Connolly and Steven Goldman and S. Romero Chaparro and Alec P Vahanian and Matti O Halinen and Jay Horrow and Jonathan L. Halperin},
  journal={American heart journal},
  year={2006},
  volume={152 5},
  pages={967-73}
}
BACKGROUND Aspirin is used in combination with anticoagulant therapy in patients with atrial fibrillation (AF), but evidence of additional efficacy is not available. METHODS We compared ischemic events and bleeding in the SPORTIF III and IV randomized trials of anticoagulation with warfarin (international normalized ratio 2-3) or fixed-dose ximelagatran. Low-dose aspirin (<100 mg/d) was allowed based on prevailing guidelines. RESULTS The 14% of patients receiving aspirin more often had… CONTINUE READING